```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable laboratory substance extensively utilized in cardiovascular studies . This antibody fragment selectively targets the glycoprotein IIb/IIIa complex on thrombocytes , inhibiting clot formation . Therefore , it's commonly employed as a method to analyze the pathways underlying thrombosis and to evaluate the effectiveness of antithrombotic therapies. Distribution is typically controlled to institutional settings.
```
Abciximab Research: Utilizing C7E3 and The 143653-53-6 Substance in Research Investigations
Ongoing studies into abciximab, a antiplatelet agent, frequently incorporates the monoclonal antibody C7E3 and the chemical compound identified as 143653-53-6. These materials are essential for examining abciximab's C7E3 mechanism of action, evaluating its therapeutic effect in various clinical settings, and exploring potential indicators of therapeutic success. Further exploration leveraging these specific reagents is predicted to generate valuable data for improving therapeutic strategies concerning cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Research Avenues with Abciximab 143653-53-6 via C7E3
Recent research demonstrate that the drug (identified as 143653-53-6) holds significant research promise, particularly when paired with C7E3. Early reports indicated that this pairing might enhance therapeutic responses in several heart-related settings. Further examination is centered on defining the exact mode of action between this inhibitor and C7E3, involving analysis of platelet cohesion and vascular protection.
- Future research work intend to refine dosing protocols.
- Animal approaches are being employed to further confirm the propositions.
- Human studies are essential to fully determine patient effectiveness.
```
Abciximab (C7E3) for Research: Specifications and Characteristics (143653-53-6)
Researchers seeking C7E3 for experimental studies should carefully consider purity and defined parameters . This product is typically provided as a lyophilized powder and thorough analytical information including verification by LC-MS, potency assays, and endotoxin level testing must be available. Verify the source’s documentation clearly states defined limits for related substances and meets established QC criteria .
High-Purity C7E3 Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the molecule C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its source . This agent is commonly utilized in laboratory investigations , particularly those involving platelet clumping and clotting . Current vendors offer this substance in varying quantities , typically ranging from mg to significant commercial supplies. We advise reviewing the certificate of quality to verify integrity and applicability for your specific use . Moreover, ensure the shelf life date before obtaining to maintain ideal effectiveness.
- Common Purity: >95%
- Storage Conditions: -20°C and controlled conditions
- Intended Purpose: Platelet Aggregation Blocking Studies